NCT02408302

Brief Summary

Currently Midazolam sedation is the standard of care for minor invasive procedures in pediatric patients; its use is restricted to two routes of administration for this purpose oral and intranasal. A third route of administration (buccal) is tested and approved for seizure management. In the investigators' study the researchers investigate the buccal route of administration versus oral or intranasal administration for sedation. The investigators' hypothesis is that buccal route of administration is more convenient than intranasal and better absorbed than oral.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Apr 2015

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2015

Completed
1 day until next milestone

Study Start

First participant enrolled

April 1, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 3, 2015

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2016

Completed
Last Updated

April 9, 2015

Status Verified

March 1, 2015

Enrollment Period

10 months

First QC Date

March 31, 2015

Last Update Submit

April 8, 2015

Conditions

Outcome Measures

Primary Outcomes (4)

  • time until sedation is achieved

    1 hour

  • duration of sedation

    time from achieving sedation until reaching full consciousness

    4 hour

  • convenience of administration

    described by the parent and the physician by a numerical rating scale (NRS) questionaire

    15 minutes

  • efficacy of the sedation

    described by the parent, nurse and physician by a NRS questionaire

    4 hours

Study Arms (3)

oral midazolam

ACTIVE COMPARATOR

oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.

Drug: Midazolam

intranasal midazolam

ACTIVE COMPARATOR

intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure

Drug: Midazolam

buccal midazolam

ACTIVE COMPARATOR

buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure

Drug: Midazolam

Interventions

comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.

Also known as: Dormicum
buccal midazolamintranasal midazolamoral midazolam

Eligibility Criteria

Age5 Months - 6 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • age 5 months to 6 years.
  • need to undergo a minimal invasive procedure that requires light sedation.
  • ASA (American Society of Anesthesiologists) I-II
  • parent that can read, understand and sign an informed consent form

You may not qualify if:

  • patients with life threatening conditions.
  • patients with respiratory or cardiac chronic illnesses or ASA other than I-II.
  • patients with traumatic injury for the nose or the oral cavity.
  • patients that would not or cannot take the drug in the route picked in a randomized way.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Carmel Medical Center

Haifa, Israel

Location

Related Publications (11)

  • Krauss B, Green SM. Sedation and analgesia for procedures in children. N Engl J Med. 2000 Mar 30;342(13):938-45. doi: 10.1056/NEJM200003303421306. No abstract available.

    PMID: 10738053BACKGROUND
  • Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet. 2006 Mar 4;367(9512):766-80. doi: 10.1016/S0140-6736(06)68230-5.

    PMID: 16517277BACKGROUND
  • American Academy of Pediatrics; American Academy of Pediatric Dentistry; Cote CJ, Wilson S; Work Group on Sedation. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics. 2006 Dec;118(6):2587-602. doi: 10.1542/peds.2006-2780.

    PMID: 17142550BACKGROUND
  • Procacci P, Francini F, Zoppi M, Maresca M. Cutaneous pain threshold changes after sympathetic block in reflex dystrophies. Pain. 1975 Jun;1(2):167-175. doi: 10.1016/0304-3959(75)90100-1.

    PMID: 1235980BACKGROUND
  • American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002 Apr;96(4):1004-17. doi: 10.1097/00000542-200204000-00031. No abstract available.

    PMID: 11964611BACKGROUND
  • Godwin SA, Caro DA, Wolf SJ, Jagoda AS, Charles R, Marett BE, Moore J; American College of Emergency Physicians. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med. 2005 Feb;45(2):177-96. doi: 10.1016/j.annemergmed.2004.11.002. No abstract available.

    PMID: 15671976BACKGROUND
  • Shavit I, Feraru L, Miron D, Weiser G. Midazolam for urethral catheterisation in female infants with suspected urinary tract infection: a case-control study. Emerg Med J. 2014 Apr;31(4):278-80. doi: 10.1136/emermed-2012-202088. Epub 2013 Feb 22.

    PMID: 23435653BACKGROUND
  • McErlean M, Bartfield JM, Karunakar TA, Whitman MC, Turley DM. Midazolam syrup as a premedication to reduce the discomfort associated with pediatric intravenous catheter insertion. J Pediatr. 2003 Apr;142(4):429-30. doi: 10.1067/mpd.2003.62.

    PMID: 12712062BACKGROUND
  • Lane RD, Schunk JE. Atomized intranasal midazolam use for minor procedures in the pediatric emergency department. Pediatr Emerg Care. 2008 May;24(5):300-3. doi: 10.1097/PEC.0b013e31816ecb6f.

    PMID: 18496113BACKGROUND
  • Wiznitzer M. Buccal midazolam is effective for acute treatment of seizures. J Pediatr. 2006 Jan;148(1):143. doi: 10.1016/j.jpeds.2005.12.008. No abstract available.

    PMID: 16440479BACKGROUND
  • Wiznitzer M. Buccal midazolam for seizures. Lancet. 2005 Jul 16-22;366(9481):182-3. doi: 10.1016/S0140-6736(05)66884-5. No abstract available.

    PMID: 16023491BACKGROUND

MeSH Terms

Interventions

Midazolam

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Muriel Konopnicki

    Carmal Medical Center, Haifa, Israel

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Muriel Konopnicki

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Pediatric emergency room

Study Record Dates

First Submitted

March 31, 2015

First Posted

April 3, 2015

Study Start

April 1, 2015

Primary Completion

February 1, 2016

Study Completion

March 1, 2016

Last Updated

April 9, 2015

Record last verified: 2015-03

Locations